| Identification | Back Directory | [Name]
Morpholine, 2-phenyl-4-[6-[[cis-3-(1H-pyrazol-1-yl)cyclobutyl]oxy]-4-pyrimidinyl]-, (2S)- | [CAS]
2761063-99-2 | [Synonyms]
Morpholine, 2-phenyl-4-[6-[[cis-3-(1H-pyrazol-1-yl)cyclobutyl]oxy]-4-pyrimidinyl]-, (2S)- | [Molecular Formula]
C21H23N5O2 | [MOL File]
2761063-99-2.mol | [Molecular Weight]
377.44 |
| Chemical Properties | Back Directory | [Boiling point ]
613.7±55.0 °C(Predicted) | [density ]
1.36±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (264.94 mM; Need ultrasonic) | [form ]
Oil | [pka]
5.85±0.26(Predicted) | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Biological Activity]
ELOVL1-IN-3 (Compound 22) is a potent and orally active inhibitor of elongation of very long chain fatty acid 1 (ELOVL1) enzyme. ELOVL1-IN-3 serves as a useful tool for researching adrenoleukodystrophy (ALD)[1]. | [storage]
Store at -20°C | [References]
[1]. Boyd MJ, et al. Discovery of Novel, Orally Bioavailable Pyrimidine Ether-Based Inhibitors of ELOVL1. J Med Chem. 2021;64(24):17777-17794. |
|
|